Targeting sialic acid-Siglec interactions to reverse immune suppression in cancer.
Glycobiology
; 28(9): 640-647, 2018 09 01.
Article
en En
| MEDLINE
| ID: mdl-29309569
ABSTRACT
Changes in sialic acids in cancer have been observed for many years. In particular, the increase of sialoglycan density or hypersialylation in tumors has been described. Recent studies have identified mechanisms for immune evasion based on sialoglycan interactions with immunoregulatory Siglec receptors that are exploited by tumor cells and microorganisms alike. Siglecs are mostly inhibitory receptors similar to known immune checkpoints including PD-1 or CTLA-4 that are successfully targeted with blocking antibodies for cancer immunotherapy. Here, we summarize the known changes of sialic acids in cancer and the role Siglec receptors play in cancer immunity. We also focus on potential ways to target these Siglec receptors or sialoglycans in order to improve anti-cancer immunity.
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Ácido N-Acetilneuramínico
/
Lectinas Similares a la Inmunoglobulina de Unión a Ácido Siálico
/
Tolerancia Inmunológica
/
Neoplasias
Límite:
Humans
Idioma:
En
Revista:
Glycobiology
Asunto de la revista:
BIOQUIMICA
Año:
2018
Tipo del documento:
Article
País de afiliación:
Suiza